Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)

Amarin Corp Plcuk (AMRN) reported Liabilities and Shareholders Equity of $645.8 million for Q1 2026, down 1.52% year-over-year from $655.7 million in Q1 2025, and down 3.73% quarter-over-quarter from $670.8 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk (AMRN) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $645.8 million in Q1 2026.

  • Liabilities and Shareholders Equity for Q1 2026 came in at $645.8 million, down 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 billion (down 8.48% YoY), and the FY2025 annual result was $670.8 million, down 2.13% from the prior year.
  • Liabilities and Shareholders Equity eased to $645.8 million in Q1 2026 per AMRN's latest filing, from $670.8 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $973.7 million in Q1 2022 and troughed at $645.8 million in Q1 2026.
  • A 5-year average of $791.8 million and a median of $799.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity dropped 17.6% in 2024, then retreated 1.52% in 2026.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $886.2 million in 2022, then decreased by 6.15% to $831.7 million in 2023, then retreated by 17.6% to $685.3 million in 2024, then decreased by 2.13% to $670.8 million in 2025, then retreated by 3.73% to $645.8 million in 2026.
  • Business Quant data shows AMRN's Liabilities and Shareholders Equity at $645.8 million in Q1 2026, $670.8 million in Q4 2025, and $659.8 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 84.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 116.58 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 200.89 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 136.46 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 128.69 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 92.50 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 56.28 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 208.00 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 86.48 Bn
10 Amarin Corp Plcuk 5.84 Bn 5.66 Bn 17.77 Mn 645.76 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 645.76 Mn
Dec 31, 2025 670.78 Mn
Sep 30, 2025 659.81 Mn
Jun 30, 2025 670.13 Mn
Mar 31, 2025 655.70 Mn
Dec 31, 2024 685.35 Mn
Sep 30, 2024 750.62 Mn
Jun 30, 2024 799.90 Mn
Mar 31, 2024 790.01 Mn
Dec 31, 2023 831.68 Mn
Sep 30, 2023 839.03 Mn
Jun 30, 2023 860.02 Mn
Mar 31, 2023 860.19 Mn
Dec 31, 2022 886.18 Mn
Sep 30, 2022 908.30 Mn
Jun 30, 2022 973.24 Mn
Mar 31, 2022 973.71 Mn
Dec 31, 2021 1.07 Bn
Sep 30, 2021 1.04 Bn
Jun 30, 2021 1.04 Bn